Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Vittorio Fusco [verfasserIn] Giuseppina Campisi [verfasserIn] Paul de Boissieu [verfasserIn] Federico Monaco [verfasserIn] Anna Baraldi [verfasserIn] Gianmauro Numico [verfasserIn] Alberto Bedogni [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid

Übergeordnetes Werk:	In: Dentistry Journal - MDPI AG, 2013, 6(2018), 3, p 42
Übergeordnetes Werk:	volume:6 ; year:2018 ; number:3, p 42

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/dj6030042

Katalog-ID:	DOAJ029722985

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ029722985
003	DE-627
005	20230307140515.0
007	cr uuu---uuuuu
008	230226s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/dj6030042 \|2 doi
035			\|a (DE-627)DOAJ029722985
035			\|a (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RK1-715
100	0		\|a Vittorio Fusco \|e verfasserin \|4 aut
245	1	0	\|a Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
650		4	\|a osteonecrosis of the jaw
650		4	\|a ONJ
650		4	\|a osteonecrosis
650		4	\|a jaw
650		4	\|a medication-related osteonecrosis of the jaw
650		4	\|a MRONJ
650		4	\|a multiple myeloma
650		4	\|a denosumab
650		4	\|a zoledronic acid
653		0	\|a Dentistry
700	0		\|a Giuseppina Campisi \|e verfasserin \|4 aut
700	0		\|a Paul de Boissieu \|e verfasserin \|4 aut
700	0		\|a Federico Monaco \|e verfasserin \|4 aut
700	0		\|a Anna Baraldi \|e verfasserin \|4 aut
700	0		\|a Gianmauro Numico \|e verfasserin \|4 aut
700	0		\|a Alberto Bedogni \|e verfasserin \|4 aut
773	0	8	\|i In \|t Dentistry Journal \|d MDPI AG, 2013 \|g 6(2018), 3, p 42 \|w (DE-627)726120650 \|w (DE-600)2681351-8 \|x 23046767 \|7 nnns
773	1	8	\|g volume:6 \|g year:2018 \|g number:3, p 42
856	4	0	\|u https://doi.org/10.3390/dj6030042 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e \|z kostenfrei
856	4	0	\|u http://www.mdpi.com/2304-6767/6/3/42 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2304-6767 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 6 \|j 2018 \|e 3, p 42

Indexfelder

author_variant	v f vf g c gc p d b pdb f m fm a b ab g n gn a b ab
matchkey_str	article:23046767:2018----::sencoioteaimeoaainseevndnsmbroernccdomnopvtlrabr
hierarchy_sort_str	2018
callnumber-subject-code	RK
publishDate	2018
allfields	10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42
spelling	10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42
allfields_unstemmed	10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42
allfieldsGer	10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42
allfieldsSound	10.3390/dj6030042 doi (DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e DE-627 ger DE-627 rakwb eng RK1-715 Vittorio Fusco verfasserin aut Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry Giuseppina Campisi verfasserin aut Paul de Boissieu verfasserin aut Federico Monaco verfasserin aut Anna Baraldi verfasserin aut Gianmauro Numico verfasserin aut Alberto Bedogni verfasserin aut In Dentistry Journal MDPI AG, 2013 6(2018), 3, p 42 (DE-627)726120650 (DE-600)2681351-8 23046767 nnns volume:6 year:2018 number:3, p 42 https://doi.org/10.3390/dj6030042 kostenfrei https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e kostenfrei http://www.mdpi.com/2304-6767/6/3/42 kostenfrei https://doaj.org/toc/2304-6767 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 6 2018 3, p 42
language	English
source	In Dentistry Journal 6(2018), 3, p 42 volume:6 year:2018 number:3, p 42
sourceStr	In Dentistry Journal 6(2018), 3, p 42 volume:6 year:2018 number:3, p 42
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid Dentistry
isfreeaccess_bool	true
container_title	Dentistry Journal
authorswithroles_txt_mv	Vittorio Fusco @@aut@@ Giuseppina Campisi @@aut@@ Paul de Boissieu @@aut@@ Federico Monaco @@aut@@ Anna Baraldi @@aut@@ Gianmauro Numico @@aut@@ Alberto Bedogni @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	726120650
id	DOAJ029722985
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029722985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307140515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/dj6030042</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029722985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vittorio Fusco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medication-related osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MRONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">denosumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">zoledronic acid</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppina Campisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul de Boissieu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federico Monaco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Baraldi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianmauro Numico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Bedogni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Dentistry Journal</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">6(2018), 3, p 42</subfield><subfield code="w">(DE-627)726120650</subfield><subfield code="w">(DE-600)2681351-8</subfield><subfield code="x">23046767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3, p 42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/dj6030042</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.mdpi.com/2304-6767/6/3/42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2304-6767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">3, p 42</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Vittorio Fusco
spellingShingle	Vittorio Fusco misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
authorStr	Vittorio Fusco
ppnlink_with_tag_str_mv	@@773@@(DE-627)726120650
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RK1-715
illustrated	Not Illustrated
issn	23046767
topic_title	RK1-715 Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid
topic	misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry
topic_unstemmed	misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry
topic_browse	misc RK1-715 misc osteonecrosis of the jaw misc ONJ misc osteonecrosis misc jaw misc medication-related osteonecrosis of the jaw misc MRONJ misc multiple myeloma misc denosumab misc zoledronic acid misc Dentistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Dentistry Journal
hierarchy_parent_id	726120650
hierarchy_top_title	Dentistry Journal
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)726120650 (DE-600)2681351-8
title	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
ctrlnum	(DE-627)DOAJ029722985 (DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e
title_full	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
author_sort	Vittorio Fusco
journal	Dentistry Journal
journalStr	Dentistry Journal
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
author_browse	Vittorio Fusco Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni
container_volume	6
class	RK1-715
format_se	Elektronische Aufsätze
author-letter	Vittorio Fusco
doi_str_mv	10.3390/dj6030042
author2-role	verfasserin
title_sort	osteonecrosis of the jaw in myeloma patients receiving denosumab or zoledronic acid. comment on pivotal trial by raje et al. published on lancet oncology
callnumber	RK1-715
title_auth	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
abstract	The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
abstractGer	The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
abstract_unstemmed	The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3, p 42
title_short	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
url	https://doi.org/10.3390/dj6030042 https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e http://www.mdpi.com/2304-6767/6/3/42 https://doaj.org/toc/2304-6767
remote_bool	true
author2	Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni
author2Str	Giuseppina Campisi Paul de Boissieu Federico Monaco Anna Baraldi Gianmauro Numico Alberto Bedogni
ppnlink	726120650
callnumber-subject	RK - Dentistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/dj6030042
callnumber-a	RK1-715
up_date	2024-07-04T00:08:03.184Z
_version_	1803604913747394560
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ029722985</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307140515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/dj6030042</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ029722985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1cdecbd91e764fc8bb3cef5e41383b5e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RK1-715</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vittorio Fusco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">osteonecrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medication-related osteonecrosis of the jaw</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MRONJ</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple myeloma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">denosumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">zoledronic acid</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dentistry</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppina Campisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul de Boissieu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Federico Monaco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Baraldi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gianmauro Numico</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alberto Bedogni</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Dentistry Journal</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">6(2018), 3, p 42</subfield><subfield code="w">(DE-627)726120650</subfield><subfield code="w">(DE-600)2681351-8</subfield><subfield code="x">23046767</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3, p 42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/dj6030042</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1cdecbd91e764fc8bb3cef5e41383b5e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.mdpi.com/2304-6767/6/3/42</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2304-6767</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2018</subfield><subfield code="e">3, p 42</subfield></datafield></record></collection>
score	7.3998413

Nicht das Richtige dabei?

Schreiben Sie uns!

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?